论文部分内容阅读
Glipizide(Minicliab,吡磺环己脲、灭糖尿,意大利产)系目前欧洲广泛应用的第二代磺脲类口服降糖药物,临床和实验研究证明具有降低血糖和提高周围胰岛素水平的作用。可改善糖尿病的代谢和微血管病变。现报告用此药物治疗10例非胰岛素依赖型糖尿病(NIDDM)病人的结果。一、材料和方法本组10例均为控制饮食及其它口服降糖药不能良好控制的NIDDM病人,其中男3例,女7例;平均年龄53岁;病程1年以内4人,1～5年3人,5年以上3人。受试者
Glipizide (Minicliab, glipizide, diabetes mellitus, made in Italy) is the second-generation sulfonylurea oral glucose-lowering drug currently widely used in Europe. Clinical and experimental studies have shown that it can lower blood sugar and improve peripheral insulin levels. Can improve the metabolism of diabetes and microvascular disease. The results of this drug treatment of 10 patients with non-insulin dependent diabetes mellitus (NIDDM) are reported. First, materials and methods The group of 10 patients are controlled diet and other oral hypoglycemic agents can not be well controlled NIDDM patients, including 3 males and 7 females; mean age 53 years; duration of less than 1 year 4, 1 to 5 3 years, 3 years more than 5 years. Subjects